Previous studies showed that in patients with low concentrations of Aβ1–42, sMRI biomarkers such as MTA and PA could predict MCI progression to AD (Van Rossum et al., 2012; Pyun et al., 2017), and also PA was associated with high levels of t-tau and p-tau (Lehmann et al., 2013). The gene discussed is MAPT; the disease is Alzheimer disease.